

## Claims of the Application:

1. (Original) A crystalline form of cetirizine monohydrochloride.
2. (Currently Amended) The crystalline form of cetirizine monohydrochloride of claim 1 having an X-ray diffraction pattern, expressed in terms of 2 theta - $2\theta$  angles and obtained with a diffractometer equipped with a copper K X-radiation source, wherein said X-ray powder diffraction pattern includes five or more peaks selected from the group consisting of peaks with 2 theta angles of  $12.97 \pm 0.09$ ,  $22.94 \pm 0.09$ ,  $20.41 \pm 0.09$ ,  $17.35 \pm 0.09$ ,  $19.15 \pm 0.09$ ,  $8.75 \pm 0.09$ ,  $14.19 \pm 0.09$ ,  $17.01 \pm 0.09$ ,  $28.28 \pm 0.09$ ,  $21.61 \pm 0.09$  and  $9.84 \pm 0.09$  degrees.
3. (Original) The crystalline form of cetirizine monohydrochloride of claim 1, wherein said X-ray diffraction pattern includes peaks with 2 theta angles of about 12.968, 22.941, 20.405, 17.348, 19.148, 8.749, 14.189, 17.01, 28.28, 21.610, and 9.842.
4. (Original) The crystalline form of cetirizine monohydrochloride of claim 1 having substantially the same X-ray diffraction pattern as shown in Figure 1.
5. (Currently Amended) The crystalline form of cetirizine monohydrochloride of claim 1 having an infrared absorption spectrum comprising absorption bands at about  $3427\text{ cm}^{-1}$ , about 2939 ~~2839~~  $\text{cm}^{-1}$ , about  $2587\text{ cm}^{-1}$ , about  $1741\text{ cm}^{-1}$ , and about  $1600\text{ cm}^{-1}$ .
6. (Original) The crystalline form of cetirizine monohydrochloride of claim 1 having substantially the same infrared spectrum as shown in Figure 2.
7. (Original) The crystalline form of cetirizine monohydrochloride of claim 1 having a differential scanning calorimetry thermogram, which exhibits an endotherm peak at about  $186\text{ }^{\circ}\text{C}$ .
8. (Original) The crystalline form of cetirizine monohydrochloride of claim 1 having substantially the same differential scanning calorimetry thermogram as shown in Figure 3.
9. (Previously amended) A composition comprising cetirizine monohydrochloride as a solid, wherein at least 80% by weight of said solid cetirizine

monohydrochloride is in a crystalline form, and one or more pharmaceutically-acceptable carriers.

10. (Original) The composition of claim 9, further comprising at least one additional form of solid cetirizine different from cetirizine monohydrochloride, said at least one different form of solid cetirizine being selected from the group consisting of cetirizine free species and cetirizine dihydrochloride.

11. (Original) The composition of claim 10, wherein said at least one different form of solid cetirizine is cetirizine dihydrochloride being present in the amount of from about 80% to about 99.5% by weight with respect to the combined weight of all solid forms of cetirizine in the composition.

12. (Original) The composition of claim 11, wherein said crystalline form of cetirizine monohydrochloride is present in the amount of from about 0.1% to about 5% by weight with respect to the combined weight of all solid forms of cetirizine in the composition.

13. (Original) The composition of claim 9, which is in the form of bulk powder suitable for use as an active ingredient in pharmaceutical formulations.

14. (Currently Amended) The composition of claim 9, where said crystalline cetirizine monohydrochloride has an X-ray diffraction pattern, expressed in terms of 2 theta angles and obtained with a diffractometer equipped with a copper K X-radiation source, wherein said X-ray powder diffraction pattern includes five or more peaks selected from the group consisting of peaks with 2 theta angles of  $12.97 \pm 0.09$ ,  $22.94 \pm 0.09$ ,  $20.41 \pm 0.09$ ,  $17.35 \pm 0.09$ ,  $19.15 \pm 0.09$ ,  $8.75 \pm 0.09$ , 14.19 ~~14.49~~  $\pm 0.09$ ,  $17.01 \pm 0.09$ ,  $28.28 \pm 0.09$ ,  $21.61 \pm 0.09$  and  $9.84 \pm 0.09$  degrees.

15. (Original) The composition of claim 9, wherein at least 90% by weight of said solid cetirizine monohydrochloride is in said crystalline form.

16. (Original) The composition of claim 9, wherein at least 95% by weight of said solid cetirizine monohydrochloride is in said crystalline form.

17. (Original) The composition of claim 9, wherein at least 99% by weight of said solid cetirizine monohydrochloride is in said crystalline form.

18. (Previously amended) A solid pharmaceutical composition, which comprises a pharmaceutically effective amount of a crystalline form of cetirizine monohydrochloride and one or more pharmaceutically acceptable carriers or diluents.

19. (Currently amended) The solid pharmaceutical composition of claim 18, wherein said crystalline form of cetirizine monohydrochloride has an X-ray diffraction pattern expressed in terms 2 theta angles and obtained with a copper K X-radiation source, wherein said X-ray powder diffraction pattern includes five or more peaks selected from the group consisting of peaks with 2 theta angles of  $12.97 \pm 0.09$ ,  $22.94 \pm 0.09$ ,  $20.41 \pm 0.09$ ,  $17.35 \pm 0.09$ ,  $19.15 \pm 0.09$ ,  $8.75 \pm 0.09$ , 14.19 ~~44.49~~  $\pm 0.09$ ,  $17.01 \pm 0.09$ ,  $28.28 \pm 0.09$ ,  $21.61 \pm 0.09$  and  $9.84 \pm 0.09$  degrees.

20. (Previously amended) The solid pharmaceutical composition of claim 18, which is a solid dosage form for oral administration.

21. (Previously amended) The solid pharmaceutical composition of claim 20, wherein said solid dosage form is a tablet.

22. (Previously amended) The solid pharmaceutical composition of claim 18, which further comprises of one or more additional active ingredients.

23. (Previously amended) The solid pharmaceutical composition of claim 22, wherein said additional active ingredient is pseudoephedrine.

24. (Previously amended) The solid pharmaceutical composition of claim 22, wherein said additional active ingredient is a leukotriene inhibitor.

25. (Previously amended) The solid pharmaceutical composition of claim 22, wherein said additional active ingredient is an analgesic.

26. (Original) A process for preparation of a crystalline form of cetirizine monohydrochloride, said process comprising:

- a. providing a solid residue of crude cetirizine monohydrochloride;
- b. contacting said crude residue with a ketone solvent to cause separation of a solid mass; and
- c. isolating said solid mass thereby obtaining said crystalline form of cetirizine

monohydrochloride.

27. (Original) The process of claim 26, further comprising providing an aqueous solution of cetirizine or salts thereof, adjusting the pH of said aqueous solution to between about 2 and about 4 with hydrochloric acid, extracting the acidified aqueous solution with a water immiscible organic solvent, and removing said water immiscible solvent to form said solid residue of cetirizine monohydrochloride.

28. (Previously amended) The process of claim 27, wherein said water immiscible organic solvent is selected from the group consisting of dichloromethane, chloroform, dichloroethane, ethyl acetate, and mixtures thereof.

29. (Original) The process of claim 27, wherein said water immiscible solvent is dichloromethane.

30. (Original) The process of claim 26, wherein said ketone solvent is selected from a group consisting of acetone, ethyl methyl ketone, methyl isobutyl ketone, and mixtures thereof.

31. (Original) The process of claim 26, wherein said ketone solvent is acetone.

32. (Original) The cetirizine monohydrochloride produced in accordance with the process of claim 26.

33. (Original) A method of treating allergic syndromes, which comprises administering a mammal in need thereof an effective amount of the compound of claim 1.

34. (Original) The method of claim 33, wherein said mammal is a human.

35. (Canceled)

36. (Canceled)

37. (Canceled)

38. (Canceled)